Smith & Nephew Signs Distribution Agreement with SI-BONE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy SNN?
Smith & Nephew (SNN) announced it has signed a distribution agreement with SI-Bone (SIBN), focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith & Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens its position in high-frequency, high-impact trauma procedures. "We're incredibly excited to partner with SI-BONE," said Scott Gunn, VP Trauma, Extremities and Shoulder. "This collaboration reflects a shared commitment to innovation, clinical excellence, and improving patient outcomes. By combining SI-BONE's industry leadership with Smith+Nephew's established commercial platform, we see a meaningful opportunity to expand access to differentiated solutions, deepen surgeon engagement, and drive sustainable growth."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNN
Wall Street analysts forecast SNN stock price to fall
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 36.680
Low
34.00
Averages
35.75
High
37.50
Current: 36.680
Low
34.00
Averages
35.75
High
37.50
About SNN
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Smith & Nephew Reports Significant Profit Increase in Fiscal 2025
- Significant Profit Growth: In fiscal 2025, Smith & Nephew's profit before tax surged to $779 million from $498 million, indicating strong performance in the medical technology sector, which is likely to boost investor confidence.
- Earnings Per Share Increase: Earnings per share rose to 71.6 cents, up from 47.0 cents last year, while adjusted earnings per share increased from 84.3 cents to 102.0 cents, reflecting the company's sustained profitability enhancement.
- Steady Revenue Growth: Total revenue grew by 6.1% to $6.16 billion, with fourth-quarter revenue reaching $1.70 billion, an 8.3% increase year-over-year, demonstrating the company's increasing competitiveness in the market.
- Dividend Increase: The Board proposed a final dividend of 24.1 cents per share, up by 1 cent from last year, with a total annual distribution of 39.1 cents, showcasing the company's confidence in future profitability and commitment to shareholder returns.
See More
Smith & Nephew Reports Q4 Revenue Growth of 8.3%
- Revenue Beats Expectations: Smith & Nephew reported Q4 revenue of $1.7 billion, reflecting an 8.3% year-over-year growth that exceeded market expectations by $20 million, indicating robust performance in the medical device sector.
- Strong Orthopaedics Performance: The Orthopaedics division achieved an underlying revenue growth of 7.9% (reported growth of 9.8%), marking the strongest quarterly growth in over two years, suggesting a rebound in market demand and enhanced product competitiveness.
- Acquisition Impact: The completion of the Integrity Orthopaedics acquisition is expected to have a marginally dilutive effect on trading profit in 2026, but is projected to be broadly neutral in 2027 and accretive by 2028, reflecting the company's confidence in future growth.
- Optimistic Future Outlook: For 2026, underlying revenue growth is expected to accelerate to around 6%, with trading profit growth anticipated at approximately 8%, alongside a commitment to achieving an adjusted ROIC exceeding 10%, demonstrating strategic determination in sustaining strong cash generation.
See More
CMA Launches Investigation into Hotel Competition
- Investigation Launched: The UK's Competition and Markets Authority (CMA) has initiated an investigation into Intercontinental Hotels, Hilton, and Marriott over suspected sharing of sensitive commercial information via a data provider, potentially violating the Competition Act 1998, which could significantly impact their operations if proven unlawful.
- Strong Financial Performance: Smith & Nephew reported a robust finish to 2025, with fourth-quarter revenue rising 8.3% to $1.7 billion and full-year revenue increasing 6.1% to $6.2 billion, alongside a 20.7% rise in operating profit to $794 million, reflecting confidence in future growth post turnaround plan.
- Stable House Prices: According to Nationwide, house price growth remained steady in February at an annual rate of 1.0% and a monthly increase of 0.3%, with the average home costing £273,176, indicating a modest recovery in the housing market amid pre-Budget uncertainties, as first-time buyer mortgage completions rose by 18%.
- Muted Market Reaction: Despite rising oil and gas prices due to tensions in the Middle East, market analysts noted a relatively muted response in financial markets, with the FTSE 100 expected to open 85 points lower, although defense stocks may surge, reflecting cautious sentiment amid potential risks.
See More
Smith+Nephew Signs Exclusive US Distribution Agreement with RMR Ortho
- Exclusive Distribution Agreement: Smith+Nephew has signed an exclusive agreement with RMR Ortho to incorporate the A'TOMIC™ Nitinol Fixation System into its Trauma, Foot & Ankle, and Hand & Wrist portfolio, aiming to enhance implant integrity and patient comfort, thereby strengthening market competitiveness.
- Portfolio Expansion: The system adds a dynamic compression fixation solution to Smith+Nephew's offerings, expected to increase its market participation in high-frequency fracture and arthrodesis procedures, further deepening engagement with surgeons.
- Manufacturing Technology Advantage: The A'TOMIC™ Nitinol Fixation System leverages proprietary manufacturing methods and the unique properties of nitinol to provide high-strength, actively compressive implants that ensure stability at fusion, fracture, and osteotomy sites, enhancing surgical success rates.
- Strategic Market Partnership: RMR Ortho CEO Joe Ritz noted that partnering with Smith+Nephew will expand access to the A'TOMIC system across the U.S., utilizing Smith+Nephew's established relationships and commercial scale to promote reliable fixation solutions.
See More
Smith+Nephew Partners with SI-BONE to Enhance Trauma Solutions
- Distribution Agreement: Smith+Nephew has signed a distribution agreement with SI-BONE, focusing on the iFuse TORQ portfolio, aimed at optimizing the product offerings for fracture fixation procedures and enhancing the company's market position in high-frequency trauma surgeries.
- Innovative Technology Introduction: The iFuse TORQ TNT implant system has received FDA Breakthrough Device Designation, which is expected to provide more effective treatment for fractures compared to traditional screws, potentially significantly improving patient outcomes.
- Economic Benefit Enhancement: iFuse TORQ TNT is eligible for Medicare New Technology Add-on Payment, allowing hospitals to receive up to $4,136 in additional reimbursement per procedure, which enhances the willingness of hospitals to adopt this technology.
- Market Expansion Opportunities: Through the partnership with SI-BONE, Smith+Nephew will expand its product coverage in the trauma sector, deepen collaboration with surgeons, and drive sustainable growth to meet the demands of a high-need market.
See More
Smith+Nephew Acquires Integrity Orthopaedics, Enhancing Shoulder Repair Technology
- Acquisition Integration: Smith+Nephew has completed the acquisition of US-based Integrity Orthopaedics, further strengthening its sports medicine shoulder repair business by offering the most comprehensive suite of rotator cuff repair technologies available, which is expected to significantly enhance market competitiveness.
- Innovative Technology: The Tendon Seam™ system from Integrity Orthopaedics features a unique repair stitch configuration and patented microanchors designed to reduce re-tear rates and improve patient outcomes, with early clinical data indicating lower re-tear rates and faster recovery compared to traditional methods.
- Market Potential: With approximately 500,000 rotator cuff repair procedures performed annually in the US, and traditional techniques suffering from structural failure rates of 20-40%, the introduction of Tendon Seam™ is poised to change this landscape, enhancing surgical success rates and patient satisfaction.
- Global Promotion Plan: Smith+Nephew plans to leverage its commercial channels in the US to accelerate the adoption of Tendon Seam™, while building a base of evidence to support global adoption, further solidifying its leadership position in the biomechanical repair sector.
See More
Smith & Nephew Reports Significant Profit Increase in Fiscal 2025
- Significant Profit Growth: In fiscal 2025, Smith & Nephew's profit before tax surged to $779 million from $498 million, indicating strong performance in the medical technology sector, which is likely to boost investor confidence.
- Earnings Per Share Increase: Earnings per share rose to 71.6 cents, up from 47.0 cents last year, while adjusted earnings per share increased from 84.3 cents to 102.0 cents, reflecting the company's sustained profitability enhancement.
- Steady Revenue Growth: Total revenue grew by 6.1% to $6.16 billion, with fourth-quarter revenue reaching $1.70 billion, an 8.3% increase year-over-year, demonstrating the company's increasing competitiveness in the market.
- Dividend Increase: The Board proposed a final dividend of 24.1 cents per share, up by 1 cent from last year, with a total annual distribution of 39.1 cents, showcasing the company's confidence in future profitability and commitment to shareholder returns.
See More
Smith & Nephew Reports Q4 Revenue Growth of 8.3%
- Revenue Beats Expectations: Smith & Nephew reported Q4 revenue of $1.7 billion, reflecting an 8.3% year-over-year growth that exceeded market expectations by $20 million, indicating robust performance in the medical device sector.
- Strong Orthopaedics Performance: The Orthopaedics division achieved an underlying revenue growth of 7.9% (reported growth of 9.8%), marking the strongest quarterly growth in over two years, suggesting a rebound in market demand and enhanced product competitiveness.
- Acquisition Impact: The completion of the Integrity Orthopaedics acquisition is expected to have a marginally dilutive effect on trading profit in 2026, but is projected to be broadly neutral in 2027 and accretive by 2028, reflecting the company's confidence in future growth.
- Optimistic Future Outlook: For 2026, underlying revenue growth is expected to accelerate to around 6%, with trading profit growth anticipated at approximately 8%, alongside a commitment to achieving an adjusted ROIC exceeding 10%, demonstrating strategic determination in sustaining strong cash generation.
See More
CMA Launches Investigation into Hotel Competition
- Investigation Launched: The UK's Competition and Markets Authority (CMA) has initiated an investigation into Intercontinental Hotels, Hilton, and Marriott over suspected sharing of sensitive commercial information via a data provider, potentially violating the Competition Act 1998, which could significantly impact their operations if proven unlawful.
- Strong Financial Performance: Smith & Nephew reported a robust finish to 2025, with fourth-quarter revenue rising 8.3% to $1.7 billion and full-year revenue increasing 6.1% to $6.2 billion, alongside a 20.7% rise in operating profit to $794 million, reflecting confidence in future growth post turnaround plan.
- Stable House Prices: According to Nationwide, house price growth remained steady in February at an annual rate of 1.0% and a monthly increase of 0.3%, with the average home costing £273,176, indicating a modest recovery in the housing market amid pre-Budget uncertainties, as first-time buyer mortgage completions rose by 18%.
- Muted Market Reaction: Despite rising oil and gas prices due to tensions in the Middle East, market analysts noted a relatively muted response in financial markets, with the FTSE 100 expected to open 85 points lower, although defense stocks may surge, reflecting cautious sentiment amid potential risks.
See More
Smith+Nephew Signs Exclusive US Distribution Agreement with RMR Ortho
- Exclusive Distribution Agreement: Smith+Nephew has signed an exclusive agreement with RMR Ortho to incorporate the A'TOMIC™ Nitinol Fixation System into its Trauma, Foot & Ankle, and Hand & Wrist portfolio, aiming to enhance implant integrity and patient comfort, thereby strengthening market competitiveness.
- Portfolio Expansion: The system adds a dynamic compression fixation solution to Smith+Nephew's offerings, expected to increase its market participation in high-frequency fracture and arthrodesis procedures, further deepening engagement with surgeons.
- Manufacturing Technology Advantage: The A'TOMIC™ Nitinol Fixation System leverages proprietary manufacturing methods and the unique properties of nitinol to provide high-strength, actively compressive implants that ensure stability at fusion, fracture, and osteotomy sites, enhancing surgical success rates.
- Strategic Market Partnership: RMR Ortho CEO Joe Ritz noted that partnering with Smith+Nephew will expand access to the A'TOMIC system across the U.S., utilizing Smith+Nephew's established relationships and commercial scale to promote reliable fixation solutions.
See More
Smith+Nephew Partners with SI-BONE to Enhance Trauma Solutions
- Distribution Agreement: Smith+Nephew has signed a distribution agreement with SI-BONE, focusing on the iFuse TORQ portfolio, aimed at optimizing the product offerings for fracture fixation procedures and enhancing the company's market position in high-frequency trauma surgeries.
- Innovative Technology Introduction: The iFuse TORQ TNT implant system has received FDA Breakthrough Device Designation, which is expected to provide more effective treatment for fractures compared to traditional screws, potentially significantly improving patient outcomes.
- Economic Benefit Enhancement: iFuse TORQ TNT is eligible for Medicare New Technology Add-on Payment, allowing hospitals to receive up to $4,136 in additional reimbursement per procedure, which enhances the willingness of hospitals to adopt this technology.
- Market Expansion Opportunities: Through the partnership with SI-BONE, Smith+Nephew will expand its product coverage in the trauma sector, deepen collaboration with surgeons, and drive sustainable growth to meet the demands of a high-need market.
See More
Smith+Nephew Acquires Integrity Orthopaedics, Enhancing Shoulder Repair Technology
- Acquisition Integration: Smith+Nephew has completed the acquisition of US-based Integrity Orthopaedics, further strengthening its sports medicine shoulder repair business by offering the most comprehensive suite of rotator cuff repair technologies available, which is expected to significantly enhance market competitiveness.
- Innovative Technology: The Tendon Seam™ system from Integrity Orthopaedics features a unique repair stitch configuration and patented microanchors designed to reduce re-tear rates and improve patient outcomes, with early clinical data indicating lower re-tear rates and faster recovery compared to traditional methods.
- Market Potential: With approximately 500,000 rotator cuff repair procedures performed annually in the US, and traditional techniques suffering from structural failure rates of 20-40%, the introduction of Tendon Seam™ is poised to change this landscape, enhancing surgical success rates and patient satisfaction.
- Global Promotion Plan: Smith+Nephew plans to leverage its commercial channels in the US to accelerate the adoption of Tendon Seam™, while building a base of evidence to support global adoption, further solidifying its leadership position in the biomechanical repair sector.
See More
